Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Unilever strategy under scrutiny after short-lived GSK skirmish

Stock MarketsJan 20, 2022 11:56AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
2/2 © Reuters. FILE PHOTO: Unilever logo is pictured on a Dove soap box in this illustration taken on January 17, 2022. REUTERS/Dado Ruvic/Illustration 2/2

By Pushkala Aripaka

(Reuters) -Unilever's strategy was under the investor microscope on Thursday after the consumer goods group effectively abandoned its 50 billion pound ($68 billion) pursuit of GlaxoSmithKline (NYSE:GSK)'s consumer healthcare business.

Shares in the maker of brands such as Dove soap and Hellmann's mayonnaise ended down 0.7% after Unilever (NYSE:UL) said on Wednesday that it would not raise a rejected offer.

It said its view on the value of the healthcare business had not changed despite GSK lifting financial forecasts for the unit, which is 32% owned by Pfizer (NYSE:PFE) and makes products such as Sensodyne toothpaste and Panadol painkillers.

Some analysts said Unilever's management, under pressure after a 31% drop in its share price since highs seen in late 2019, had been wise not to be drawn into upping their bid for a business that GSK has said it wants to spin off.

Barclays (LON:BARC) analysts called it a "smart move," saying that the decision "shows that whilst Unilever remains very keen on the asset, it is disciplined and will not do the deal at any price."

Others said the proposed mega-deal, which would have been one of the largest ever on the London market, had been unexpected and raised questions about Unilever's plan under Chief Executive Alan Jope for a more gradual shift away from lower-margin goods to health, beauty and hygiene products.

"From our discussions with shareholders and Unilever share price action, we believe there is a clear discontent with management and the board over the changed strategy and focus on transformative M&A," J.P. Morgan analysts said in a note.

Meanwhile, a group of investors said they had filed a fresh resolution urging Unilever to address a "crucial blind spot" and set ambitious targets to sell healthier foods.

Last week, Terry Smith, whose Fundsmith vehicle is Unilever's 13th biggest investor, lambasted the company for being "obsessed" with promoting its sustainability credentials at the expense of performance.

Smith took aim at Unilever again on Thursday, labelling the bid "a near death experience," and reiterating calls to focus on the operating performance of the existing business "before taking on any more challenges".

'CALLED THEIR BLUFF'

GSK, led by Chief Executive Emma Walmsley, has stuck to its plans to spin off the consumer healthcare unit despite previous pressure from activist investors to consider alternatives.

It had rejected three approaches from Unilever, and the final proposal made on Dec. 20 comprised 41.7 billion pounds in cash and 8.3 billion pounds in Unilever shares.

GSK's stock closed down 2% on Thursday.

"Unilever cannot increase any offer, not because the value of GSK's consumer (unit) would not warrant it, but simply because Unilever's investors expressed a no-confidence vote on Unilever's CEO doing any deal of this size," a GSK investor, who declined to be named, told Reuters.

Barclays analysts asked if GSK had overplayed its hand.

"By saying (GSK) sees £50 billion as fundamentally undervaluing the business, it now makes it very difficult to accept the £50 billion on the table whilst still saving face," they said.

"Some investors think that Glaxo may have overplayed their hand and Unilever has called their bluff."

Other large targets could be available for Unilever, with the consumer remedies industry, traditionally a part of the prescription drug sector, undergoing major transformation.

Johnson & Johnson (NYSE:JNJ) in November unveiled plans to spin off its consumer health division, owner of Listerine and Baby Powder brands, to focus on pharmaceuticals and medical devices.

($1 = 0.7328 pounds)

Unilever strategy under scrutiny after short-lived GSK skirmish
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email